| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007691-199512000-00017 |
| P698 | PubMed publication ID | 8588235 |
| P50 | author | Philip F Halloran | Q40000948 |
| P2093 | author name string | L Shaw | |
| K Gallicano | |||
| D W Holt | |||
| M Oellerich | |||
| A Lindholm | |||
| V W Armstrong | |||
| K Wonigeit | |||
| B Kahan | |||
| R Yatscoff | |||
| P433 | issue | 6 | |
| P921 | main subject | lake | Q23397 |
| organ transplantation | Q69253852 | ||
| P304 | page(s) | 642-654 | |
| P577 | publication date | 1995-12-01 | |
| P1433 | published in | Therapeutic Drug Monitoring | Q15724567 |
| P1476 | title | Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel | |
| P478 | volume | 17 |
| Q38089593 | A review on therapeutic drug monitoring of immunosuppressant drugs. |
| Q81283349 | A role for cytokine measurement in therapeutic monitoring of immunosuppressive drugs following lung transplantation |
| Q44137772 | A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation |
| Q44971336 | An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation |
| Q81458437 | An in vitro system for the determination of individualized immunosuppression |
| Q35827273 | Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients |
| Q73635011 | Biochemical characterization of the minor immunophilins |
| Q44173471 | Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? |
| Q36554704 | Chronopharmacokinetics of ciclosporin and tacrolimus |
| Q46812684 | Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation |
| Q73027638 | Comparison of cyclosporine immunoassays (AxSYM and RIA) for assessing pharmacokinetic parameters in liver transplant patients |
| Q73040136 | Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients |
| Q81482562 | Comparison of three methods for cyclosporine therapeutic monitoring |
| Q52907056 | Conversion of cardiac and liver transplant recipients from HPLC and FPIA (polyclonal) to an FPIA (monoclonal) technique for measurement of blood cyclosporin A. |
| Q73194059 | Current opinions on therapeutic drug monitoring of immunosuppressive drugs |
| Q35759193 | Cyclosporin therapeutic drug monitoring--an established service revisited. |
| Q77369580 | Cyclosporine A: peak or trough level monitoring in renal transplant recipients? |
| Q35711226 | Cyclosporine in thoracic organ transplantation |
| Q34360395 | Cyclosporine therapeutic drug monitoring |
| Q73599284 | Cytotoxicity assessment of three therapeutic agents, cyclosporin-A, cisplatin and doxorubicin, with the ciliated protozoan Tetrahymena pyriformis |
| Q35494854 | Estimation of Abbreviated Cyclosporine A Area under the Concentration-Time Curve in Allogenic Stem Cell Transplantation after Oral Administration |
| Q43702763 | Evaluation and comparison of therapeutic monitoring of whole-blood levels of cyclosporin A and its metabolites in renal transplantation by HPLC and RIA methods |
| Q44199739 | Evaluation of essential parameters in the chromatographic determination of cyclosporin A and metabolites using a D-optimal design |
| Q77725003 | Evaluation of the AxSYM CyA assay compared with HPLC, TDx monoclonal and EMIT with both pretreatments |
| Q94359956 | Experience with cyclosporine |
| Q33636541 | Generic drugs: the Canadian perspective |
| Q33636544 | Generic immunosuppressants: the European perspective |
| Q73325454 | High-performance liquid chromatographic method for therapeutic drug monitoring of cyclosporine A and its two metabolites in renal transplant patients |
| Q43635709 | High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood |
| Q34558567 | Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations |
| Q52204722 | Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations. |
| Q44405616 | Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. |
| Q43875084 | Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants |
| Q74377401 | Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood |
| Q34053149 | Mini-review: therapeutic drug monitoring in pediatrics |
| Q73491264 | Minor immunophilin binding of tacrolimus and sirolimus metabolites |
| Q42973580 | Multicenter analytical evaluation of the automated electrochemiluminescence immunoassay for cyclosporine |
| Q44491040 | Neoral monitoring by limited sampling area under the concentration time curve in stable indian renal transplant recipients |
| Q32139680 | New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine |
| Q52237037 | Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). |
| Q43585783 | Optimized analytical method for cyclosporin A by high-performance liquid chromatography-electrospray ionization mass spectrometry. |
| Q77757637 | Parent cyclosporine in whole blood by monoclonal fluorescence polarization immunoassay for axsym and monoclonal enzyme-multiplied immunoassay for cobas-fara |
| Q34554442 | Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients |
| Q46830629 | Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients |
| Q73027324 | Population pharmacokinetics of cyclosporine in kidney transplant patients |
| Q44373816 | Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients |
| Q43789008 | Provision of laboratory services for heart and lung transplantation in Australia |
| Q38636104 | Recent Advances in Analytical Methods for the Therapeutic Drug Monitoring of Immunosuppressive Drugs |
| Q44064642 | Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve |
| Q44604540 | Simple determination of cyclosporine in human whole blood by high-performance liquid chromatography |
| Q74532781 | Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and ciclosporin in blood by liquid chromatography-electrospray mass spectrometry |
| Q41401735 | Target concentration strategy for cyclosporin monitoring |
| Q52272529 | The EMIT Cyclosporine Assay: development of application protocols for the Boehringer Mannheim Hitachi 911 and 917 analyzers. |
| Q46420434 | The V-twin system (Dade Behring Laboratories): a useful tool for immunosuppressive drug monitoring |
| Q41724238 | The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates |
| Q41201521 | The use of therapeutic drug monitoring to optimise immunosuppressive therapy |
| Q35711356 | Therapeutic drug monitoring of cyclosporine |
| Q77166098 | Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus |
| Q33610775 | Therapeutic drug monitoring of immunosuppressant drugs. |
| Q81962585 | Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral |
| Q79819511 | Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience |
| Q40769608 | Transport activity and surface expression of the Na+-Ca2+ exchanger NCX1 are inhibited by the immunosuppressive agent cyclosporin A and by the nonimmunosuppressive agent PSC833. |
| Q44822760 | Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late post-transplant period |
| Q46452813 | Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection |
| Q73357644 | Whole blood cyclosporin monitoring in liver and heart transplant patients: evaluation of the specificity of a fluorescence polarization immunoassay and an enzyme-multiplied immunoassay technique |
| Q43003617 | Whole blood flow cytometric measurement of NFATc1 and IL-2 expression to analyze cyclosporine A-mediated effects in T cells |
Search more.